Skip to main content
. 2019 Jan 7;25:193–239. doi: 10.12659/MSM.912294

Figure 7.

Figure 7

The histone methyltransferase (HMT) predictor-score analysis of 399 prostate cancer patients in the Cancer Genome Atlas (TCGA) cohort. (A) Expression profile of four histone methyltransferases (HMTs) in high-risk and low-risk patients. (B) Kaplan-Meier plot shows the recurrence-free survival (RFS) in high-risk and low-risk patients. (C) A time-dependent area under the receiver operating characteristics (AUROC) curve was used to assess the prognostic value of the four HMT gene prognostic signature (EZH2, SETD5, SMYD1, and SUV420H2). The AUC for the four HMT gene prognostic signature model at one, three, and five years were 0.717, 0.690, and 0.720, respectively via cross-validation (purple).